The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Academic Article uri icon

Overview

MeSH Major

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Cyclophosphamide
  • Cytochrome P-450 Enzyme System
  • Immunologic Factors
  • Immunosuppressive Agents
  • Receptors, IgG
  • Rituximab

abstract

  • The finding that the homozygous FcγRIIa 519AA variant was associated with complete response and a shorter time to complete response in the RAVE trial, independent of treatment type, implies that FcγRIIa may be broadly involved in disease pathogenesis and response to therapy.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/art.39822

PubMed ID

  • 27482943

Additional Document Info

start page

  • 169

end page

  • 175

volume

  • 69

number

  • 1